摘要
注射用利培酮微球是第一个长效非典型抗精神病药,结合了长效剂型和非典型抗精神病药的优势。其血浆药物水平稳定,疗效明显优于安慰剂,且同于口服利培酮。注射用利培酮微球为大量需要长期抗精神病药物治疗的患者提供了一个先进可行的治疗选择。注射用利培酮微球不良反应少,耐受性佳,可改善患者生活质量和社会功能,并为医师和患者提供了一个新的治疗模式,可以作为第一线抗精神病药物单一使用。其再住院和复发的风险也较低,具有较好的效益成本性。本文从注射用利培酮微球的作用机制、临床疗效和安全性等方面进行了综述。
Risperidone long-acting injection（RLAI,a microsphere） is the first long-acting atypical antipsychotic.It combines with long-acting conventional antipsychotics with advantages of oral atypical antipsychotics.Its plasma level is stable;its curative effect obviously surpasses placebo,and equally to oral risperidone.RLAI provides an option available in the treatment of a wide range of patients requiring long-term antipsychotic therapy.RLAI is efficacious and well tolerated.It provides a new mode of treatment for both clinicians and patients,and can improve the outcome of health-related quality of life and social performance,and can be used as the first line antipsychotic for monotherapy.Rehospitalization and relapse risks are lower after treatment with RLAI,so it is more cost-effective.this paper mainly introduced its mechanism of action,clinical effect and safety.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2010年第22期2066-2069,共4页
Chinese Journal of New Drugs
关键词
注射用利培酮微球
疗效
安全性
药物经济学
剂量模型
risperidone long-acting injection
efficacy
safety
pharmacoeconomics
dose-response modeling
